PPRC1 is a prognostic biomarker and key regulator of mitochondrial oxidative phosphorylation in multiple myeloma

TL;DR

PPRC1 is a new biomarker in multiple myeloma that predicts poor survival and supports cancer cell energy production through mitochondrial function.

Contribution

PPRC1 is identified as a novel prognostic biomarker and regulator of mitochondrial oxidative phosphorylation in multiple myeloma.

Findings

PPRC1 is upregulated in MM and linked to advanced disease and poor survival.

PPRC1 knockdown reduces cell proliferation and impairs oxidative phosphorylation.

PPRC1 correlates with immune cell infiltration and oncogenic pathways in MM.

Abstract

Multiple myeloma (MM) remains an incurable haematological malignancy, underscoring the need for novel prognostic biomarkers and therapeutic targets. This study aimed to investigate the clinical and biological significance of peroxisome proliferator-activated receptor gamma coactivator-related protein 1 (PPRC1) in MM.

Expression and clinical data were obtained from public databases and an independent local cohort. Kaplan–Meier and Cox regression analyses were performed to evaluate prognostic value. Differential expression analysis, pathway enrichment analysis and single-cell RNA-seq data analysis were used to explore biological functions. PPRC1 was silenced in MM cell lines using siRNA to assess its effects on cell survival and oxidative phosphorylation.

PPRC1 was significantly upregulated in MM and was associated with advanced disease stage and poor overall survival. Multivariate Cox analysis identified PPRC1 as an independent prognostic factor. A nomogram incorporating PPRC1 and revised-ISS improved survival prediction. Functional analyses revealed that PPRC1 was positively correlated with oxidative phosphorylation and oncogenic signalling pathways. A potential connection between PPRC1 expression and immune cell infiltration was observed. PPRC1 knockdown inhibited cell proliferation, induced cell cycle arrest and apoptosis and impaired oxidative phosphorylation in MM.

PPRC1 acts as a prognostic biomarker and metabolic regulator in MM by sustaining mitochondrial oxidative phosphorylation. These findings highlight PPRC1 as a potential therapeutic target in MM.

Figures